File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: European guidelines on managing adverse effects of medication for ADHD

TitleEuropean guidelines on managing adverse effects of medication for ADHD
Authors
KeywordsADHD
Adverse
Children
European
Guidelines
HKS
Medication
Issue Date2011
PublisherDr Dietrich Steinkopff Verlag. The Journal's web site is located at http://link.springer.de/link/service/journals/00787/index.htm
Citation
European Child And Adolescent Psychiatry, 2011, v. 20 n. 1, p. 17-37 How to Cite?
AbstractThe safety of ADHD medications is not fully known. Concerns have arisen about both a lack of contemporary-standard information about medications first licensed several decades ago, and signals of possible harm arising from more recently developed medications. These relate to both relatively minor adverse effects and extremely serious issues such as sudden cardiac death and suicidality. A guidelines group of the European Network for Hyperkinetic Disorders (EUNETHYDIS) has therefore reviewed the literature, recruited renowned clinical subspecialists and consulted as a group to examine these concerns. Some of the effects examined appeared to be minimal in impact or difficult to distinguish from risk to untreated populations. However, several areas require further study to allow a more precise understanding of these risks. © 2010 The Author(s).
Persistent Identifierhttp://hdl.handle.net/10722/171415
ISSN
2023 Impact Factor: 6.0
2023 SCImago Journal Rankings: 2.175
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorGraham, Jen_US
dc.contributor.authorBanaschewski, Ten_US
dc.contributor.authorBuitelaar, Jen_US
dc.contributor.authorCoghill, Den_US
dc.contributor.authorDanckaerts, Men_US
dc.contributor.authorDittmann, RWen_US
dc.contributor.authorDöpfner, Men_US
dc.contributor.authorHamilton, Ren_US
dc.contributor.authorHollis, Cen_US
dc.contributor.authorHoltmann, Men_US
dc.contributor.authorHulpkeWette, Men_US
dc.contributor.authorLecendreux, Men_US
dc.contributor.authorRosenthal, Een_US
dc.contributor.authorRothenberger, Aen_US
dc.contributor.authorSantosh, Pen_US
dc.contributor.authorSergeant, Jen_US
dc.contributor.authorSimonoff, Een_US
dc.contributor.authorSonugaBarke, Een_US
dc.contributor.authorWong, ICKen_US
dc.contributor.authorZuddas, Aen_US
dc.contributor.authorSteinhausen, HCen_US
dc.contributor.authorTaylor, Een_US
dc.date.accessioned2012-10-30T06:14:02Z-
dc.date.available2012-10-30T06:14:02Z-
dc.date.issued2011en_US
dc.identifier.citationEuropean Child And Adolescent Psychiatry, 2011, v. 20 n. 1, p. 17-37en_US
dc.identifier.issn1018-8827en_US
dc.identifier.urihttp://hdl.handle.net/10722/171415-
dc.description.abstractThe safety of ADHD medications is not fully known. Concerns have arisen about both a lack of contemporary-standard information about medications first licensed several decades ago, and signals of possible harm arising from more recently developed medications. These relate to both relatively minor adverse effects and extremely serious issues such as sudden cardiac death and suicidality. A guidelines group of the European Network for Hyperkinetic Disorders (EUNETHYDIS) has therefore reviewed the literature, recruited renowned clinical subspecialists and consulted as a group to examine these concerns. Some of the effects examined appeared to be minimal in impact or difficult to distinguish from risk to untreated populations. However, several areas require further study to allow a more precise understanding of these risks. © 2010 The Author(s).en_US
dc.languageengen_US
dc.publisherDr Dietrich Steinkopff Verlag. The Journal's web site is located at http://link.springer.de/link/service/journals/00787/index.htmen_US
dc.relation.ispartofEuropean Child and Adolescent Psychiatryen_US
dc.subjectADHD-
dc.subjectAdverse-
dc.subjectChildren-
dc.subjectEuropean-
dc.subjectGuidelines-
dc.subjectHKS-
dc.subjectMedication-
dc.subject.meshAdrenergic Uptake Inhibitors - Administration & Dosage - Adverse Effectsen_US
dc.subject.meshAttention Deficit Disorder With Hyperactivity - Drug Therapy - Psychologyen_US
dc.subject.meshCardiovascular Diseases - Chemically Induced - Diagnosis - Mortality - Prevention & Controlen_US
dc.subject.meshCentral Nervous System Stimulants - Administration & Dosage - Adverse Effectsen_US
dc.subject.meshChilden_US
dc.subject.meshClinical Trials As Topicen_US
dc.subject.meshDrug Administration Scheduleen_US
dc.subject.meshDrug Dosage Calculationsen_US
dc.subject.meshDrug Toleranceen_US
dc.subject.meshDrug Utilization Reviewen_US
dc.subject.meshEuropeen_US
dc.subject.meshHumansen_US
dc.subject.meshMonitoring, Physiologic - Methods - Standardsen_US
dc.subject.meshPropylamines - Administration & Dosage - Adverse Effectsen_US
dc.subject.meshRisk Assessmenten_US
dc.subject.meshSubstance-Related Disorders - Etiology - Prevention & Controlen_US
dc.subject.meshSuicide, Attempted - Prevention & Control - Psychologyen_US
dc.titleEuropean guidelines on managing adverse effects of medication for ADHDen_US
dc.typeArticleen_US
dc.identifier.emailWong, ICK:wongick@hku.hken_US
dc.identifier.authorityWong, ICK=rp01480en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1007/s00787-010-0140-6en_US
dc.identifier.pmid21042924-
dc.identifier.scopuseid_2-s2.0-78651514054en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-78651514054&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume20en_US
dc.identifier.issue1en_US
dc.identifier.spage17en_US
dc.identifier.epage37en_US
dc.identifier.isiWOS:000287397900003-
dc.publisher.placeGermanyen_US
dc.identifier.scopusauthoridGraham, J=23566712800en_US
dc.identifier.scopusauthoridBanaschewski, T=6603935963en_US
dc.identifier.scopusauthoridBuitelaar, J=26640178500en_US
dc.identifier.scopusauthoridCoghill, D=6603562184en_US
dc.identifier.scopusauthoridDanckaerts, M=6602331008en_US
dc.identifier.scopusauthoridDittmann, RW=7005218961en_US
dc.identifier.scopusauthoridDöpfner, M=7003632659en_US
dc.identifier.scopusauthoridHamilton, R=35412881500en_US
dc.identifier.scopusauthoridHollis, C=7006624553en_US
dc.identifier.scopusauthoridHoltmann, M=7003350416en_US
dc.identifier.scopusauthoridHulpkeWette, M=6603417658en_US
dc.identifier.scopusauthoridLecendreux, M=6603152108en_US
dc.identifier.scopusauthoridRosenthal, E=7102028321en_US
dc.identifier.scopusauthoridRothenberger, A=7005835367en_US
dc.identifier.scopusauthoridSantosh, P=6701465826en_US
dc.identifier.scopusauthoridSergeant, J=7004036780en_US
dc.identifier.scopusauthoridSimonoff, E=7003772384en_US
dc.identifier.scopusauthoridSonugaBarke, E=7005682785en_US
dc.identifier.scopusauthoridWong, ICK=7102513915en_US
dc.identifier.scopusauthoridZuddas, A=7003979777en_US
dc.identifier.scopusauthoridSteinhausen, HC=7102832892en_US
dc.identifier.scopusauthoridTaylor, E=7403206584en_US
dc.identifier.citeulike8209856-
dc.identifier.issnl1018-8827-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats